Compare Innovative Industrial Properties Inc (IIPR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs Sanofi SA — how do they compare? Innovative Industrial Properties Inc trades at $51.76 (market cap $1.43B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 66.6× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays the higher dividend (14.64%). Which is the better fit depends on your goals — on Pluang, investors hold Innovative Industrial Properties Inc for 86 Days and Sanofi SA for 94 Days on average.
| IIPR | SNY | |
|---|---|---|
Market Cap | $1.43B | $95.18B |
Volume | 394,222 | 2,995,646 |
Sector | Real Estate | Health |
52-Week High | $64.67 | $52.34 |
52-Week Low | $44.58 | $39.51 |
Typical Hold Time | 86 Days | 94 Days |
Enterprise Value | $1.96B | $114.48B |
Dividend Yield | 14.64% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $51.87, up 1.25% on the day, with a bearish technical signal from moving averages. The stock shows mixed earnings, beating in Q2 but missing in Q1, with revenue declining to $266 million in 2025. Valuation ratios appear attractive with a P/E of 11.75 and P/B of 0.83, while the company maintains a high net income margin of 52.27%. Recent news highlights a $245 million mezzanine loan commitment and a declared $1.90 dividend.
The outlook is cautious due to declining revenue and negative net cash flow in 2025, offset by strong profitability and a discounted valuation. Risks include tenant defaults and dividend sustainability concerns, but analyst consensus suggests upside with a $84.67 price target. The stock presents a high-yield opportunity with significant re-rating potential if operational challenges are managed.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
